GlobeNewswire
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
📊
AI Sentiment
Positive
7/10
- Home
- SLDB
as of 12-12-2025 3:44pm EST
$5.86
$0.01
-0.26%
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Chart Type:
Time Range:
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 464.1M | IPO Year: | 2018 |
| Target Price: | $14.82 | AVG Volume (30 days): | 987.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.41 - $7.37 | Next Earning Date: | 11-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered SLDB Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 4 days ago
AI Recommendation
hold
Model Accuracy: 72.97%
72.97%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
Hanrahan Jessie
Sell
Chief Regulatory Officer
SLDB Dec 3, 2025
Avg Cost/Share
$5.11
Shares
4,483
Total Value
$22,908.13
Owned After
26,660
SEC Form 4
Howton David T
Sell
Chief Operating Officer
SLDB Dec 3, 2025
Avg Cost/Share
$5.11
Shares
4,932
Total Value
$25,202.52
Owned After
32,908
SEC Form 4
Herzich Paul
Sell
Chief Technology Officer
SLDB Dec 3, 2025
Avg Cost/Share
$5.11
Shares
2,701
Total Value
$13,802.11
Owned After
26,622
SEC Form 4
Cumbo Alexander
Sell
President and CEO
SLDB Dec 3, 2025
Avg Cost/Share
$5.11
Shares
10,808
Total Value
$55,228.88
Owned After
81,388
SEC Form 4
Ganot Ilan
Sell
Director
SLDB Nov 10, 2025
Avg Cost/Share
$4.12
Shares
3,278
Total Value
$13,505.36
Owned After
95,412
SEC Form 4
Brooks Gabriel
Sell
Chief Medical Officer
SLDB Oct 20, 2025
Avg Cost/Share
$5.96
Shares
2,895
Total Value
$17,254.20
Owned After
33,819
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Dec 3, 2025 | Sell | $5.11 | 4,483 | $22,908.13 | 26,660 | |
| Howton David T | SLDB | Chief Operating Officer | Dec 3, 2025 | Sell | $5.11 | 4,932 | $25,202.52 | 32,908 | |
| Herzich Paul | SLDB | Chief Technology Officer | Dec 3, 2025 | Sell | $5.11 | 2,701 | $13,802.11 | 26,622 | |
| Cumbo Alexander | SLDB | President and CEO | Dec 3, 2025 | Sell | $5.11 | 10,808 | $55,228.88 | 81,388 | |
| Ganot Ilan | SLDB | Director | Nov 10, 2025 | Sell | $4.12 | 3,278 | $13,505.36 | 95,412 | |
| Brooks Gabriel | SLDB | Chief Medical Officer | Oct 20, 2025 | Sell | $5.96 | 2,895 | $17,254.20 | 33,819 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
Compare SLDB vs Leading Stocks
See how SLDB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.